Patent Classification

Animal Model, Diseases/Transgenic/Transplantation/Cloning

1. Disease model incorporation into an artificial immune system (AIS)
    
2. Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method
    
3. Transgenic mouse for screening and for studies of the pharmacodynamics and pharmacokinetics of ligands acting on the oestrogen receptor and its intracellular receptors, and method for the preparation thereof
    
4. Transgenic animals secreting desired proteins into milk
    
5. Methods of screening an agent for an activity in an isolated eye of a teleost
    
6. Method for producing polyunsaturated long-chain fatty acids in transgenic organisms
    
7. Autoimmune disease model animal
    
8. Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
    
9. Mouse with deficiency of glutamate transporter GLAST function
    
10. Mouse models of human prostate cancer
     
11. Transgenic cell and gene recombinant animal having a mutant SDHC gene derived from mammals
     
12. Non human animals with human-glial chimeric brains
     
13. Transgenic chickens that lay eggs containing exogenous proteins
     
14. Alzheimer model for drug screening
     
15. Rat model of diabetic nephropathy
     
16. Transgenic rats and spermatogonial stem cells
     
17. Humanized anti-cmet antibodies
     
18. Artificial human chromosome containing human antibody a light chain gen
     
19. Human .alpha. synuclein expressing transgenic mice
     
20. Transgenic non-human mammals as models for human pathologies of stem cell origin
     
21. Transgenic nonhuman mammals producing fibrinogen in milk and methods of producing fibrin
     
22. Transgenic bovines having reduced prion protein production
     
23. Animal models for demyelination disorders
     
24. Methods for introducing heterologous cells into fish to determine if the heterologous cells contain cancer cells or a pathogen
     
25. Non-human animal exhibiting bone metastasis of tumor cells
     
26. Transgenic pigs carrying both hHO-1 and hDAF transgenes for xenotransplantation
     
27. 7B2 knockout transgenic animals as models of endocrine disease
     
28. Glycosylated interferon alpha obtained from a transgenic chicken
     
29. Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
     
30. Human monoclonal antibodies against interleukin 8 (IL-8)
     
31. Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents
     
32. Animal model of human hematopoietic tumor
     
33. Chimeric mouse model for endometriosis
     
34. Recombinant promoters in avian cells
     
35. Transgenic animal containing CD200 and uses therefor
     
36. Use of EDG2 receptor in an animal model of heart failure
     
37. Transgenic mice comprising a genomic human tau transgene
     
38. CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
     
39. Histamine receptor H3 modified transgenic mice
     
40. Production of humanized antibodies in transgenic animals
     
41. Mouse models of human prostate cancer
     
42. Nude mouse model for human neoplastic disease
     
43. Transgenic mouse expressing constitutively active hydrocarbon receptor
     
44. Animal model for allergic disorders
     
45. Breeding and milking cows for milk free of .beta.-casein A¹
     
46. Transgenic pathogen-resistant organism
     
47. Material and methods for the production of sperm and analysis thereof
     
48. Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
     
49. Method for cloning animals with targetted genetic alterations by transfer of long-term cultured male or female somatic cell nuclei, comprising artificially-induced genetic alterations, to enucleated recipient cells
     
50. Autoimmune disease model animal
     
51. Skeletal cell model to screen anti-diabetic compounds
    
 
52. Stress-responsive induction of a therapeutic agent and methods of use
     
53. Mouse disease model for evaluation of prophylactic and therapeutic treatments of Chlamydia
     
54. Transgenic non-human animals capable of producing heterologous antibodies
     
55. Obesity gene
     
56. Human inflammatory breast carcinoma xenograft capable of lymphovascular invasion and methods for its use
     
57. Transgenic mammals expressing mutant GP IIIa
     
58. Transgenic mice expressing a human SXR receptor polypeptide
     
59. Animal models and methods for sepsis
     
60. Transgenic mice overexpressing aspartyl protease 2 (ASP2)
     
61. Transgenic animals having a modified glycoprotein V gene
     
62. Methods of assessing the effect of a gene of interest on human prostate cancer progression
     
63. Three dimensional vaginal tissue model containing immune cells
     
64. Transgenic mice comprising a constitutively-activated MEK5 and exhibiting cardiac hypertrophy and dilated cardiomyopathy
     
65. Transgenic mice containing glucagon receptor gene disruptions
     
66. Animal model system for photodamage, photoaging and skin wounding
     
67. Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof
     
68. Transgenic non-human animals expressing a truncated activintype II receptor
     
69. Transgenic animals as urinary bioreactors for the production of polypeptide in the urine, recombinant DNA construct for kidney-specific expression, and method of using same
     
70. Rodent model for Parkinson's Disease
     
71. Methods and compositions for screening for angiogenesis modulating compounds
     
72. In vitro ischemia model
     
73. Method of assaying modulators of hypertension
     
74. Three-dimensional in vitro model of human preneoplastic breast disease
     
75. Production of replicative hepatitis C virus
     
76. Methods of simulating human prostate cancer progression
     
77. Mouse mammary tumor lines expressing estrogen and progesterone receptors
     
78. Model for Alzheimer's disease and other neurodegenerative diseases
     
79. Methods for identifying contraceptive compounds
     
80. Transgenic mice containing BMP gene disruptions
     
81. Transgenic animal and methods
     
82. Transgenic mice containing intestinal alkaline phosphatase gene disruptions
     
83. Knockout mouse for the tumor suppressor gene ANX7
     
84. Transgenic mice containing retina-specific nuclear receptor gene disruptions
     
85. Method for selecting a transgenic mouse model of alzheimer's disease
     
86. Human antibodies derived from immunized xenomice
     
87. Animal model
     
88. Method for investigating the suitability of a material as a medicament
     
89. Transgenic mouse model of basal cell carcinoma
     
90. Mice comprising engrafted functional human hepatocytes
     
91. Transgenic mouse model for cardiac hypertrophy and methods of use thereof
     
92. Transgenic mice exhibiting increased susceptibility to seizures
     
93. Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
     
94. Transgenic swine having HLA-D gene, swine cells thereof and xenografts therefrom
     
95. Method for the production of in vivo model of hepatocellular carcinoma without lung metastasis
     
96. 5-HT3 receptor assay using transgenic mammal
     
97. Use of drosophila melanogaster as a model for screening psychostimulant plant material
     
98. Epidermis/dermis equivalents and aged skin equivalents shaped therefrom
     
99. Models of chronic and acute inflammatory diseases
     
100. Lymphoma-susceptible transgenic mice and methods for studying drug sensitivity of lymphomas
      
101. Ovariectomized mouse model for human menopause
      
102. Animal model for detection of vulnerable plaques
      
103. Animal model for transplantation
      
104. Method for inducing hepatic fibrosis by repeated administration of allylalcohol
      
105. Large animal model of invasive pulmonary aspergillosis in an immunocompromised host
      
106. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
     
     
107. Mice models of human prostate cancer progression
     
     
108. Nude mouse model for the growth and treatment of human neurally-derived tumors
     
     
109. Vitamin D receptor ablated mice
     
     
110. Rodent models of human amyloidoses
      
     
111. Transgenic model of heart failure
      
112. 25-hydroxyvitamin D3 24-hydroylase transgenic rats
      
     
113. Model for chronic cerebral inflammation by intracerebral injection of double stranded RNA
      
     
114. Method of using mouse model for evaluation of HIV vaccines
      
     
115. Transgenic model and treatment for heart disease
      
     
116. Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
      
     
117. Non-transgenic rodent model of alzheimer's disease

Antibodies/Antigens

1. Glycoengineered, recombinant antibody
    
2. Method for immobilizing glycoprotein
    
3. Method for determining the immunogenicity of an antigen
    
4. Polynucleotides encoding heavy and light chains of antibodies to OPGL
    
5. Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation
    
6. Characterization and identification of unique human adiponectin isoforms and antibodies
    
7. Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
    
8. Method of detecting red cell antigen-antibody reactions
    
9. Nucleic acids encoding humanized anti-tag 72 CC49 antbodies
    
10. Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
     
11. Immunoglobulins
     
12. Methods and compositions to evaluate antibody treatment response
     
13. Antibody purification by protein a and ion exchange chromatography
     
14. Methods of purifying anti A .beta. antibodies
     
15. Methods of purifying Fc region containing proteins
     
16. Antibodies that inhibit TSLP activity
     
17. Antibody composition-producing cell
     
18. Methods of screening agonistic antibodies
     
19. Fusion antibodies
     
20. Bivalent IgY antibody constructs for diagnostic and therapeutic applications
     
21. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
     
22. Antibodies that bind CCX-CKR2
     
23. Human CTLA-4 antibodies and their uses
     
24. Cytokine zalpha11 ligand fusion proteins
     
25. Antibodies which bind specifically to activin receptor like kinases
     
26. Antibodies to M-CSF
     
27. Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
     
28. Antibodies against LLG polypeptides of the triacylglycerol lipase family
     
29. Antibodies to human vascular endothelial growth factor 2 and methods of using the same
     
30. PRO34128 antibodies
     
31. Bispecific antibody molecule
     
32. Humanized Fc.gamma.RIIB-specific antibodies and methods of use thereof
     
33. Antibody pair screening methods
     
34. Metalloproteinase-binding proteins
     
35. Enhancing the circulating half-life of antibody-based fusion proteins
     
36. Multivalent antibody constructs
     
37. Human antibodies to human delta like ligand 4
     
38. Antibody against G-protein coupled receptor showing selective affinity for ATP and uses therefor
     
39. Artificial human chromosome containing human antibody a light chain gen
     
40. PAK4-related antibodies
     
41. Humanized anti-CD4 antibody with immunosuppressive properties
     
42. Antibodies that recognize hyperproliferative cells and methods of making and using same
     
43. Conformationally abnormal forms of tau proteins and specific antibodies thereto
     
44. Antibodies binding the TNF related protein, TNF-Y
     
45. Antibody composition-producing cell
     
46. Antibodies to PRO1550 polypeptides
     
47. Antigen transduced T cells used as a delivery system for antigens
     
48. Transgenic algae for delivering antigens to an animal
     
49. Antibodies which bind human CXCR3
     
50. Therapeutic and diagnostic conjugates for use with multispecific antibodies
     
51. Erythropoietin receptor binding antibodies
     
52. Method for generating diversity
     
53. Nucleic acids encoding human TNF-.alpha. convertase
     
54. DIRS1 antibodies
     
55. TAG-72 specific C.sub.H2 domain deleted antibodies
     
56. Monoclonal antibody hPAM4
     
57. Chimeric and humanized antibodies to .alpha.5.beta.1 integrin that modulate angiogenesis
     
58. Detection of antibodies to squalene in serum
     
59. Humanised antibodies
     
60. Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3
     
61. Human monoclonal antibody against hepatitis C virus E2 glycoprotein
     
62. Humanised antibodies
     
63. PR0994 antibodies
     
64. Monoclonal antibody cPAM4
     
65. Antibodies and methods for generating genetically altered antibodies with high affinity
     
66. Human antibodies that bind human 17-A1/EpCAM tumor antigen
     
67. Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
     
68. Equine Fc epsilon receptor alpha protein
     
69. Real time detection of antigens
     
70. Antibody recognizing proliferative human liver cells, proliferative human liver cells and functional human liver cells
     
71. Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
     
72. Anti-CD40 monoclonal antibody
     
73. Polypeptide variants with altered effector function
     
74. Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72
     
75. Methods of optimizing antibody variable region binding affinity
     
76. Antibodies that recognize and bind phosphorylated human androgen receptor and methods of using same
     
77. Method for producing human antibodies in SCID mice which uses dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents
     
78. Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
     
79. Antibodies to human chemokine beta-9
     
80. Enhancing the circulating half-life of antibody-based fusion proteins
     
81. Human TIMP-1 antibodies
     
82. Monoclonal antibody specific for advanced glycosylation endproducts in biological samples
     
83. Molecular database for antibody characterization
     
84. Method for producing monoclonal antibodies
     
85. Altered antibodies
     
86. Compositions and methods for detection of antibody binding to cells
     
87. Compositions and methods for generating chimeric heteromultimers
     
88. Antibodies to receptor protein tyrosine kinases
     
89. Method and antibody for imaging breast cancer
     
90. Human antibodies derived from immunized xenomice
     
91. Antibodies specific for growth differentiation factor-7
     
92. Method for making humanized antibodies
     
93. Monoclonal antibody against human telomerase catalytic subunit
     
94. Polypeptide variants
     
95. Monoclonal antibody to the clonotypic structure of a T-cell receptor, a pharmaceutical compostion and a diagnostic reagent comprising the same
    
    
96. Antibodies with increased binding affinity

Bioavailability/Absorption, Enhancer/Modifier/Anti-First-Pass

1. Composition to enhance the bioavailability of curcumin
    
2. Compositions and methods for enhancing receptor-mediated cellular internalization
    
3. Dendrimers as molecular translocators
    
4. Method for improving adsorption of a drug from ethylene oxide derivative
    
5. Method and system for measuring the penetration of drugs and other substances into tissue
    
6. Solid oral dosage form containing an enhancer
    
7. Methods of enhancing solubility of agents
    
8. Absorption enhancers such as e.g. BHT, BHA or propyl gallate
    
9. System to monitor the ingestion of medicines
    
10. Pulsatile release compositions and methods for enhanced intestinal oligonucleotide drug absorption
     
11. Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
     
12. Prodrugs of pharmaceuticals with improved bioavailability
     
13. Enhancing the circulating half-life of antibody-based fusion proteins
     
14. Enhanced transport using membrane disruptive agents
     
15. Modified chimeric polypeptides with improved pharmacokinetic properties
     
16. Method of predicting drug-food interaction
     
17. Enhancing the circulating half-life of antibody-based fusion proteins
     
18. Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
     
19. Antifungal compositions with improved bioavailability
     
20. Bioavailable composition of natural and synthetic HCA
     
21. Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
     
22. Fenofibrate pharmaceutical composition having high bioavailabilty
     
23. Mineral absorption enhancer
     
24. Method for increasing the serum half-life of a biologically active molecule
     
25. Preparations for evaluating eliminative ability of stomach
     
26. Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
     
27. Composition comprising pharmaceutical/nutraceutical agent and a bio-enhancer obtained from Glycyrrhiza glabra
     
28. Solid-state form of celecoxib having enhanced bioavailability
     
29. Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
     
30. Method for increasing the serum half-life of a biologically active molecule
     
31. Intracellular glucocorticoid-induced leucine zippers modulators of apoptic cell death pathways
     
32. Composition and method for potentiating drugs
     
33. Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition
     
34. Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
     
35. Fenofibrate pharmaceutical composition having high bioavailability
     
36. Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors
     
37. Compositions containing therapeutically active components having enhanced solubility
     
38. Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
     
39. Basic drug compositions with enhanced bioavailability
     
40. Orally administrable composition capable of providing enhanced bioavailability when ingested
     
    
41. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
     
    
42. Self-assembled taxo-diterpenoid nanostructures
     
    
43. Bactericidal/permeability-increasing protein (BPI) compositions
     
    
44. Anti-first-pass effect compounds and citrus extract
     
    
45. Pharmaceutical composition containing acid addition salt of basic drug
     
    
46. Dissolution of triprolidine hydrochloride
     
    
47. Transcytosis vehicles and enhancers for drug delivery
     
    
48. Composition for enhanced uptake of polar drugs from the colon
     
    
49. Method for reducing absorption of undesired lipids in the gastrointestinal tract
     
    
50. Use of essential oils to increase bioavailability of orally administered pharmaceutical compounds
     
    
51. Compositions and methods for altering the biodistribution of biological agents
     
    
52. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
     
    
53. Potentiation of immune responses with liposomal adjuvants
     
    
54. Compositions for increased bioavailability of carotenoids
     
    
55. Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents
     
    
56. Orally administrable composition capable of providing enhanced bioavailability when ingested
     
    
57. Unit dosage forms for treatment of vasoconstriction and related conditions
     
    
58. Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
     
    
59. Use of piperine as a bioavailability enhancer

Biocatalysis

1. Direct encapsulation of biomacromolecules in surfactant templated mesoporous and nanoporous materials
    
2. Pathogen-targeted biocatalysts
    
   
3. Methods using cross linked protein crystal formulations as catalysts in organic solvents